Phosphodiesterase inhibitors: Factors that influence potency, selectivity, and action

Handbook of Experimental Pharmacology

Volumn 204, Issue , 2011, Pages 47-84

  Francis, Sharron H ^a   Houslay, Miles D ^b   Conti, Marco ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Compartmentation; Cyclic AMP; Cyclic GMP; PDE1; PDE10; PDE11; PDE2; PDE3; PDE4; PDE5; PDE6; PDE7; PDE8; PDE9; Phosphodiesterase; Phosphodiesterase inhibitors

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; BAY 736691; CILOMILAST; CP 671305; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; D 159687; DIPYRIDAMOLE; IC 86340; NITRAQUAZONE; PAPAVERINE; PHOSPHODIESTERASE 9; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VII; ROFLUMILAST; ROLIPRAM; RS 25344; RS 33793; SCH 51866; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; PHOSPHODIESTERASE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN ISCHEMIA; CATALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; HYDROLYSIS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; CLASSIFICATION; ENZYME ACTIVE SITE; PHYSIOLOGY; REVIEW;

ANIMALS; CATALYTIC DOMAIN; DRUG DESIGN; HUMANS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN STRUCTURE, QUATERNARY;

EID: 79960896132     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-17969-3_2     Document Type: Article

References (192)

1. Abdulkadir Coban T, Beydemir S, Gucin I, Ekinci D, Innocenti A, Vullo D, Supuran CT (2009) Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV. Bioorg Med Chem 17:5791-5795
2. Alvarez R, Sette C, Yang D, Eglen R, Wilhelm R, Shelton ER, Conti M (1995) Activationand selective Inhibitionof acyclic AMP- specificphosphodiesterase, PDE4D3. MolPharmacol 48:616-622
3. Aravind L, Ponting CP (1997) The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22:458-459 (Pubitemid 27515909)
4. Baillie GS, Huston E, Scotland G, Hodgkin M, Gall I, Peden AH, MacKenzie C, Houslay ES, Currie R, Pettitt R, Walmsley AR, Wakelam MJO, Warwicker J, Houslay MD (2002) TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 277:28298-28309 (Pubitemid 34966785)
5. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, Houslay MD (2003) b-arrestin mediated PDE4 cAMP phosphodiesterase recruitment regulates b2-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci 100:940-945 (Pubitemid 36183934)
6. Barnes P (2006) Theophylline for COPD. Thorax 61:742-744 (Pubitemid 44369394)
7. Barnes AP, Livera G, Huang P, Sun C, ONeal WK, Conti M, Stutts MJ, Milgram SL (2005) Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 280:7997-8003 (Pubitemid 40349697)
8. Barren B, Gakhar L, Muradov H, Boyd KK, Ramaswamy S, Artemyev NO (2009) Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit. EMBO J 28:3613-3622
9. Bazhin AV, Tambor V, Dikov B, Philippov PP, Schadendorf D, Eichmuller SB (2010) cGMPphosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells. Cell Mol Life Sci 67:817-828
10. Beavo JA, Brunton LL (2002) Cyclic nucleotide research -still expanding after half a century. Nat Rev Mol Cell Biol 3:710-718 (Pubitemid 34987792)
11. Beltman J, Becker DE, Butt E, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995) Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. Mol Pharmacol 47:330-339
12. Bender AT, Beavo J (2006) Cyclic nucleotide phosphodiesterases: molecualr regulation to clinical use. Pharmacol Rev 58:488-520 (Pubitemid 44394910)
13. Bessay E, Blount M, Zoraghi R, Beasley A, Grimes K, Francis S, Corbin JD (2008) Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. J Pharmacol Exp Ther 325:62-68 (Pubitemid 351439156)
14. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152 (Pubitemid 38822097)
15. Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH (2006) A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol Pharmacol 70:1822-1831
16. Blount MA, Zoraghi R, Bessay EP, Beasley A, Francis SH, Corbin JD (2007) Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. J Pharmacol Exp Ther 323:730-737 (Pubitemid 350005117)
17. Bolger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, Riggs M, Wigler M, Ferguson K (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13:6558-6571 (Pubitemid 23292650)
18. Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD (2003) Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 278:33351-33363 (Pubitemid 37055787)
19. Bolger GB, Conti M, Houslay MD (2006) Cellular functions of phosphodiesterase-4 enzymes. In: Beavo J, Francis S, Houslay MD (eds) Phosphodiesterases in health and disease. CRC, Boca Raton, pp 99-130, Ch. 6
20. Bos JL (2006) Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 31:680-686 (Pubitemid 44791945)
21. Braumann T, Erneux C, Petridis G, Stohrer WD, Jastorff B (1986) Hydrolysis of cyclic nucleotides by a purified cGMP-stimulated phosphodiesterase: structural requirements for hydrolysis. Biochim Biophys Acta 871:199-206 (Pubitemid 16085079)
22. Burgers PM, Eckstein F (1979) Stereochemistry of internucleotide bond formation by polynucleotide phosphorylase from Micrococcus luteus. Biochemistry 18:450-454
23. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28:63-70
24. Butcher RW, Sutherland EW (1962) Adenosine 30, 50-phosphate in biological materials. I. Purification and properties of cyclic 30, 50-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 30, 50-phosphate in human urine. J Biol Chem 237:1244-1250
25. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995) Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins. Mol Pharmacol 47:340-347
26. Castro LR, Verde I, Cooper DM, Fischmeister R (2006) Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113:2221-2228
27. Charbonneau H (1990) Structure-function relationships among cyclic nucleotide phosphodiesterases. In: Beavo J, Houslay MD (eds) Cyclic nucleotide phosphodiesterases: structure, regulation and drug action. Wiley, New York, pp 267-296
28. Chen G, Wang H, Robinson H, Cai J, Wan Y, Ke H (2008) An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies. Biochem Pharmacol 75:1717-1728
29. Cheung PP, Yu L, Zhang H, Colman RW (1998) Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis. Arch Biochem Biophys 360:99-104 (Pubitemid 29010918)
30. Collins DM, Murdoch H, Dunlop AJ, Charych E, Baillie GS, Herberg FW, Brandon N, Prinz A, Houslay MD (2008) Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cell Signal 20:2356-2369
31. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
32. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496 (Pubitemid 36800786)
33. Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729-13732
34. Corbin JD, Sugden PH, Lincoln TM, Keely SL (1977) Compartmentalization of adenosine 30:50-monophosphate and adenosine 30:50-monophosphate-dependent protein kinase in heart tissue. J Biol Chem 252:3854-3861 (Pubitemid 8127237)
35. Corbin JD, Turko IV, Beasley A, Francis SH (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760-2767 (Pubitemid 30304274)
36. Corbin JD, Blount MA, Weeks JL 2nd, Beasley A, Kuhn KP, Ho YS, Saidi LF, Hurley JH, Kotera J, Francis SH (2003) [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 63:1364-1372 (Pubitemid 36627232)
37. Cortijo J, Bou J, Beleta J, Cardelus I, Llenas J, Morcillo E, Gristwood RW (1993) Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 108:562-568 (Pubitemid 23032571)
38. Cote RH (2006) Photoreceptor phosphodiesterase (PDE6): aG-protein-activated PDE regulatingvisual excitation in rod and cone photoreceptor cells. In: Beavo J, Francis SH, Houslay MD(eds) Cyclic nucleotidephosphodiesterasesinhealthanddisease. CRC Press, Boca Raton, pp 165-193
39. Dent G, Rabe K (1996) Effects of theophylline and non-selective xanthine derivatives on PDE isoenzymes and cellular function. In: Schudt C, Dent G, Rabe KF (eds) Handbook of immunopharmacology: phosphodiesterase inhibitors. Academic, San Diego, pp 41-64
40. Erneux C, Miot F, Boeynaems JM, Dumont JE (1982) Paradoxical stimulation by 1-methyl-3-isobutylxanthine of rat liver cyclic AMP phosphodiesterase activity. FEBS Lett 142:251-254 (Pubitemid 12050506)
41. Fink TL, Francis SH, Beasley A, Grimes KA, Corbin JD (1999) Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem 274:34613-34620 (Pubitemid 129509498)
42. Francis SH, Corbin JD (1999) Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36:275-328 (Pubitemid 29431414)
43. Francis SH, Corbin JD (2005) Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. Urol Clin North Am 32:419-429 (Pubitemid 41607530)
44. Francis SH, Corbin JD (2009) Phosphodiesterase-5. In: Bradshaw RA, Dennis EA (eds) Handbook of cell signaling, vol 2, 2nd edn. Academic, Oxford, pp 1439-1444
45. Francis SH, Colbran JL, McAllister-Lucas LM, Corbin JD (1994) Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J Biol Chem 269:22477-22480 (Pubitemid 24273347)
46. Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA, Corbin JD (2006) Phosphodiesterase-5: molecular characteristics relating to structure, function, and regulation. In: Beavo SHF JA, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 131-164
47. Francis SH, Morris GZ, Corbin JD (2008) Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 20: 333-342
48. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998) YC-1 potentiates nitric oxide-and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54:962-967 (Pubitemid 29002038)
49. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127:195-203 (Pubitemid 29213249)
50. Giembycz MA (2006) Reinventing the wheel: nonselective phosphodiesterase inhibitors for chronic inflammatory diseases. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 649-665
51. Gopal VK, Francis SH, Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 268:3304-3312 (Pubitemid 32823005)
52. Goraya TA, Cooper DM (2005) Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. Cell Signal 17:789-797 (Pubitemid 40353649)
53. Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE (2006) cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281:2841-2846 (Pubitemid 43845749)
54. Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Francis SH, Conti M, Houslay MD (eds) Phosphodiesterases as drug targets. Springer, Heidelberg
55. Han P, Sonati P, Rubin C, Michaeli T (2006) PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C. J Biol Chem 281:15050-15057 (Pubitemid 43855093)
56. Handa N, Mizohata E, Kishishita S, Toyama M, Morita S, Uchikubo-Kamo T, Akasaka R, Omori K, Kotera J, Terada T, Shirouzu M, Yokoyama S (2008) Crystal structure of theGAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem 283:19657-19664
57. Hayes JS, Brunton LL, Brown JH, Reese JB, Mayer SE (1979) Hormonally specific expression of cardiac protein kinase activity. Proc Natl Acad Sci USA 76:1570-1574 (Pubitemid 9175360)
58. He F, Seryshev AB, Cowan CW, Wensel TG (2000) Multiple zinc binding sites in retinal rod cGMP phosphodiesterase, PDE6alpha beta. J Biol Chem 275:20572-20577 (Pubitemid 30457641)
59. Heikaus CC, Stout JR, Sekharan MR, Eakin CM, Rajagopal P, Brzovic PS, Beavo JA, Klevit RE (2008) Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem 283:22749-22759
60. Hirano T, Yamagata T, Gohda M, Yamagata Y, Ichikawa T, Yanagisawa S, Ueshima K, Akamatsu K, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M (2006) Inhibition of reactive nitrogen specids production in COPD airways: comparison between inhaled corticosteroid and oral theophylline. Thorax 61:761-766 (Pubitemid 44369399)
61. Hoffmann R, Wilkinson IR, McCallum JF, Engels P, Houslay MD (1998) cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 333:139-149 (Pubitemid 28342503)
62. Houslay MD (2001) Intracellular targeting and regulation of PDE4 cAMP specific Phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315
63. Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35:91-100
64. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18 (Pubitemid 36259414)
65. Houslay MD, Adams DR (2010) Lockdown on phosphodiesterase-4. Nat Biotechnol 28:38-40
66. Houslay MD, Schafer P, Zhang K (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519 (Pubitemid 41527193)
67. Houslay MD, Baillie GS, Maurice DH (2007) cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100:950-966 (Pubitemid 46598920)
68. Huai Q, Wang H, Sun Y, Kim HY, Liu Y, Ke H (2003) Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 11:865-873 (Pubitemid 36833272)
69. Huai Q, Wang H, Zhang W, Colman RW, Robinson H, Ke H (2004) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA 101(26):9624-9629 (Pubitemid 38869286)
70. Huang D, Hinds TR, Martinez SE, Doneanu C, Beavo JA (2004) Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase. J Biol Chem 279:48143-48151 (Pubitemid 39540969)
71. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, Houslay MD (1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344 (Pubitemid 26408583)
72. Huston E, Houslay TM, Baillie GS, Houslay MD (2006) cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochem Soc Trans 34:504-509 (Pubitemid 44230748)
73. Huston E, Lynch M, Mohamed A, Collins DM, Hill EV, MacLeod R, Krause E, Baillie GS, Houslay MD (2008) EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proc Natl Acad Sci USA 105:12791-12796
74. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899 (Pubitemid 26347710)
75. Jarvest RL, Lowe G, Baraniak J, Stec WJ (1982) A stereochemical investigation of the hydrolysis of cyclic AMP and the (Sp)-and (Rp)-diastereoisomers of adenosine cyclic 30:50-phosphorothioate by bovine heart and bakers-yeast cyclic AMP phosphodiesterases. Biochem J 203:461-470
76. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDEindependent mechanism. Proc Natl Acad Sci USA 107:9795-9800
77. Jin SL, Swinnen JV, Conti M (1992) Characterization of the structure of a lowKm, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. J Biol Chem 267:18929-18939
78. Jin SC, Richard FJ, Kuo WP, DErcole AJ, Conti M (1999) Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA 96: 11998-12003 (Pubitemid 29502847)
79. Juilfs DM, FÜlle HJ, Zhao AZ, Houslay MD, Garbers DL, Beavo JA (1997) A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci USA 94:3388-3395 (Pubitemid 27157322)
80. Kalgutkar AS, Choo E, Taylor TJ, Marfat A (2004) Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica 34:755-770 (Pubitemid 39487050)
81. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F (2003) Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9:2289-2302 (Pubitemid 37236353)
82. Kambayashi J, Shakur Y, Liu Y (2006) Bench to bedside: multiple actions of the PDE3 inhibitor cilostazol. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 627-648
83. Kang KK, Ahn GJ, Sohn YS, Ahn BO, Kim WB (2003) DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J Int Med Res 31:517-528 (Pubitemid 38008687)
84. Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101:1084-1095 (Pubitemid 350146434)
85. Ke H, Wang EH (2007a) Structure, catalytic mechanism, and inhibitor selectivity of cyclic nucleotide phosphodiesterases. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. Taylor & Francis Group, LLC, Boca Raton, pp 607-626
86. Ke H, Wang H (2007b) Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 7:391-403 (Pubitemid 46358652)
87. Keravis T, Lugnier C (2010) Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des 16(9):1114-1125
88. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan C (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104:2338-2343 (Pubitemid 33049518)
89. Klabunde RE (1983) Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 93:21-26 (Pubitemid 13005927)
90. Kobayashi M, Nasuhara Y, Betsuyaku T, Shibuya E, Tanino Y, Tanino M, Takamura K, Nagai K, Hosokawa T, Nishimura M (2004) Effect of low-dose theophylline on airway inflammation in COPD. Respirology 9:249-254 (Pubitemid 38937400)
91. Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, Huang Z (2000) Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39:6449-6458 (Pubitemid 30347150)
92. Laliberte F, Liu S, Gorseth E, Bobechko B, Bartlett A, Lario P, Gresser MJ, Huang Z (2002) In vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Lett 512:205-208 (Pubitemid 34164479)
93. Li X, Baillie GS, Houslay MD (2009) Mdm2 directs the ubiquitination of barrestin-sequestered cAMP phosphodiesterase-4D5. J Biol Chem 284:16170-16182
94. Lim J, Pahlke G, Conti M (1999) Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain. J Biol Chem 274:19677-19685
95. Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, Menniti FS (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci USA 105:13309-13314
96. Livi GP, Kmetz P, McHale MM, Cieslinski LB, Sathe GM, Taylor DP, Davis RL, Torphy TJ, Balcarek JM (1990) Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase. Mol Cell Biol 10:2678-2686
97. Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F (2010) Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci USA 107:5646-5651
98. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD (2005) RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with {beta}Arrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the {beta}2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells. J Biol Chem 280:33178-33189 (Pubitemid 41397113)
99. MacFarland RT, Zelus BD, Beavo JA (1991) High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem 266:136-142 (Pubitemid 21906101)
100. Martinez SE, Beavo JA, Hol WG (2002a) GAF domains: two billion year old molecular switches that bind cyclic nucleotides. Mol Interv 2:317-323
101. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, Beavo JA (2002b) The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci USA 99:13260-13265
102. Martinez SE, Bruder S, Schultz A, Zheng N, Schultz JE, Beavo JA, Linder JU (2005) Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization. Proc Natl Acad Sci USA 102:3082-3087 (Pubitemid 40299919)
103. Martinez SE, Heikaus CC, Klevit RE, Beavo JA (2008) The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change. J Biol Chem 283:25913-25919
104. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD (2005) In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 17:1158-1173 (Pubitemid 40933535)
105. McPhee I, Yarwood SJ, Huston E, Scotland G, Beard MB, Ross AH, Houslay ES, Houslay MD (1999) Association with the src family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition. J Biol Chem 274:11796-11810
106. Mery PF, Pavoine C, Pecker F, Fischmeister R (1995) Erythro-9-(2-hydroxy- 3-nonyl) adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 48:121-130
107. Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, Xu H, Florio V, Rybalkin SD, Beavo JA, Chen YF, Li JD, Blaxall BC, Abe J, Yan C (2009) Role of Ca2+/calmodulinstimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105:956-964
108. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, ZaccoloM(2004) Fluorescence resonance energy transferbased analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67-75 (Pubitemid 38931837)
109. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung Y-F, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M (2006) Compartmentalised phosphodiesterase-2 (PDE2) activity blunts b-adrenergic cardiac inotropy via a b3-adrenoceptor/NO/cGMP dependent pathway. Circ Res 98:226-234
110. Mullershausen F, Russwurm M, Friebe A, Koesling D (2004) Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109:1711-1713 (Pubitemid 38500670)
111. Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klussmann E, Porteous DJ, Millar JK, Houslay MD (2007) Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci 27:9513-9524 (Pubitemid 47358203)
112. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA (2008) Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 326:380-387
113. Obernolte R, Bhakta S, Alvarez R, Bach C, Zuppan P, Mulkins M, Jarnagin K, Shelton ER (1993) The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. Gene 129:239-247
114. Ohshiro H, Tonai-Kachi H, Ichikawa K (2008) GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem Biophys Res Commun 365:344-348 (Pubitemid 350137295)
115. Omburo GA, Jacobitz S, Torphy TJ, Colman RW (1998) Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant human phosphodiesterase 4A. Cell Signal 10:491-497 (Pubitemid 28404433)
116. Omori K, Kotera J (2006) PDE11. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 255-274
117. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309-327
118. Owen DR, Walker JK, Jon Jacobsen E, Freskos JN, Hughes RO, Brown DL, Bell AS, Brown DG, Phillips C, Mischke BV, Molyneaux JM, Fobian YM, Heasley SE, Moon JB, Stallings WC, Joseph Rogier D, Fox DN, Palmer MJ, Ringer T, Rodriquez-Lens M, Cubbage JW, Blevis-Bal RM, Benson AG, Acker BA, Maddux TM, Tollefson MB, Bond BR, Macinnes A, Yu Y (2009) Identification, synthesis and SAR of amino substituted pyrido[3, 2b]pyrazinones as potent and selective PDE5 inhibitors. Bioorg Med Chem Lett 19:4088-4091
119. Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS (2009) Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci USA 106:18225-18230
120. Penmatsa H, Zhang W, Yarlagadda S, Li C, Conoley VG, Yue J, Bahouth SW, Buddington RK, Zhang G, Nelson DJ, Sonecha MD, Manganiello V, Wine JJ, Naren AP (2010) Compartmentalized cyclic adenosine 30, 50-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell 21:1097-1110
121. Poppe H, Rybalkin SD, Rehmann H, Hinds TR, Tang XB, Christensen AE, Schwede F, Genieser HG, Bos JL, Doskeland SO, Beavo JA, Butt E (2008) Cyclic nucleotide analogs as probes of signaling pathways. Nat Methods 5:277-278 (Pubitemid 351455143)
122. Puxeddu E, Uhart M, Li CC, Ahmad F, Pacheco-Rodriguez G, Manganiello VC, Moss J, Vaughan M (2009) Interaction of phosphodiesterase 3 Awithbrefeldin A-inhibited guaninenucleotide-exchangeproteins BIG1 and BIG2 and effect on ARF1 activity. Proc Natl AcadSci USA 106: 6158-6163
123. Rabe KF, Magnussen H, Dent G (1995) Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 8:637-642
124. Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, Karpen JW (2001a) A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc Natl Acad Sci USA 98:13049-13054 (Pubitemid 33051315)
125. Rich TC, Tse TE, Rohan JG, Schaack J, Karpen JW (2001b) In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors. J Gen Physiol 118:63-78
126. Rich TC, Xin W, Mehats C, Hassell KA, Piggott L, Le X, Karpen JW, Conti M (2006) Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells. Am J Physiol Cell Physiol 292:C319-C331 (Pubitemid 46115141)
127. Richter W, Conti M (2002) Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J Biol Chem 277:40212-40221 (Pubitemid 35215591)
128. Richter W, ContiM(2004) The oligomerization state determines regulatory properties and inhibitor sensitivityoftype4cAMP-specificphosphodiesterases. JBiolChem279:30338-30348 (Pubitemid 38937961)
129. Rocque WJ, Holmes WD, Patel IR, Dougherty RW, Ittoop O, Overton L, Hoffman CR, Wisely GB, Willard DH, Luther MA (1997) Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high-and low-affinity (R)-rolipram binding. Protein Exp Purif 9:191-202 (Pubitemid 27210714)
130. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG, Beavo JA (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100:2611-2621 (Pubitemid 27514902)
131. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291 (Pubitemid 37048240)
132. Rybalkina IG, Tang XB, Rybalkin SD (2010) Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms. Mol Pharmacol 77:670-677
133. Salanova M, Jin SC, Conti M (1998) Heterologous expression and purification of recombinant rolipram-sensitive cyclic AMP-specific phosphodiesterases. Methods 14:55-64
134. Saldou N, Baecker PA, Li B, Yuan Z, Obernolte R, Ratzliff J, Osen E, Jarnagin K, Shelton ER (1998) Purification and physical characterization of cloned human cAMP phosphodiesterases PDE-4D and -4C. Cell Biochem Biophys 28:187-217 (Pubitemid 128533776)
135. Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB, Becker JW, Van der Ploeg LH, Tota MR (2004) Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43:6091-6100 (Pubitemid 38669477)
136. Schaper W (2005) Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther 19:357-363 (Pubitemid 43029821)
137. Schultz JE, Dunkern T, Gawlitta-Gorka E, Sorg G (2011) The GAF-tandem domain of phosphodiesterase 5 as a potential drug target. Francis SH, Conti M, HouslayMD (eds) Phosphodiesterases as drug targets. Springer, Heidelberg
138. Scotland G, Houslay MD (1995) Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (rPDE-IVA1;RNPDE4A1A) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyl transferase (CAT). Biochem J 308:673-681
139. Sekhar KR, Grondin P, Francis SH, Corbin JD (1996) Design and synthesis of xanthines and cyclic GMP analogues as potent inhibitors of PDE5. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors. Academic, New York, pp 135-146
140. Serebruany V, Sabaeva E, Booze C, Atar OD, Eisert C, Hanley D (2009) Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. Thromb Haemost 102:538-543
141. Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 271:16526-16534 (Pubitemid 26239006)
142. Shakur Y, Pryde J, Houslay MD (1993) Engineered deletion of the unique N-terminal domain of the cyclic AMP specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem J 292:677-686 (Pubitemid 23210195)
143. Smith KJ, Scotland G, Beattie J, Trayer IP, Houslay MD (1996) Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by 1H-NMR and identification of the membrane association domain using chimeric constructs. J Biol Chem 271:16703-16711 (Pubitemid 26239033)
144. Smith KJ, Baillie GS, Hyde EI, Li X, Houslay TM, McCahill A, Dunlop AJ, Bolger GB, Klussmann E, Adams DR, Houslay MD (2007) 1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1. Cell Signal 19:2612-2624 (Pubitemid 47542301)
145. Souness JE, Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227-236 (Pubitemid 27271642)
146. Stasch JP, Hobbs AJ (2009) NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191:277-308
147. Steinberg SF, Brunton LL (2001) Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41:751-773 (Pubitemid 32385905)
148. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59:347-356 (Pubitemid 30015963)
149. Sullivan M, Egerton M, Shakur Y, Marquardsen A, Houslay MD (1994) Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA, cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1). Cell Signal 6:793-812
150. Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425:98-102 (Pubitemid 37101725)
151. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA (2005a) cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96:100-109 (Pubitemid 40095759)
152. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA (2005b) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222 (Pubitemid 40321358)
153. Taniguchi Y, Tonai-Kachi H, Shinjo K (2006) Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 580:5003-5008 (Pubitemid 44332369)
154. Tasken KA, Collas P, Kemmner WA, Witczak O, Conti M, Tasken K (2001) Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J Biol Chem 276:21999-22002
155. Tenor H, Hatzelmann A, Beume R, Lahu G, Zech K, Bethke TD (2011) Pharmacology, clinical efficacy and tolerability of PDE4 inhibitors: Impact of human pharmacokinetics. Francis SH, Conti M, HouslayMD (eds) Phosphodiesterases as drug targets. Springer, Heidelberg
156. Thomas MK, Francis SH, Beebe SJ, Gettys TW, Corbin JD (1992) Partial mapping of cyclic nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic nucleotide analogues. Adv Second Messenger Phosphoprotein Res 25:45-53
157. Thompson WJ (1991) Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther 51:13-33
158. Tian G, Rocque WJ, Wiseman JS, Thompson IZ, Holmes WD, Domanico PL, Stafford JA, Feldman PL, Luther MA (1998) Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate. Biochemistry 37:6894-6904 (Pubitemid 28228126)
159. Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G (2008) Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 154:787-796 (Pubitemid 351821591)
160. Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351-370 (Pubitemid 28090521)
161. Trifilieff A, Wyss D, Walker C, Mazzoni L, Hersperger R (2002) Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1, 2, 5]oxadiazol-5-yl-[1, 7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1, 7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther 301:241-248 (Pubitemid 34250301)
162. Turko IV, Ballard SA, Francis SH, Corbin JD (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 56:124-130 (Pubitemid 29309820)
163. Uhler MD (1993) Cloning and expression of a novel cyclic GMP-dependent protein kinase from mouse brain. J Biol Chem 268:13586-13591 (Pubitemid 23307789)
164. Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, Corbin JD, Francis SH, Kukreja RC, Movsesian MA (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330:884-891
165. Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, OConnor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S (2009) Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia (dagger) dagger Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1). J Med Chem 52:5188
166. Walseth TF, Gander JE, Eide SJ, Krick TP, Goldberg ND (1983) 18O labeling of adenine nucleotide alpha-phosphoryls in platelets. Contribution by phosphodiesterase-catalyzed hydrolysis of cAMP. J Biol Chem 258:1544-1558 (Pubitemid 13101360)
167. Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM (1997) Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun 234:320-324 (Pubitemid 27243900)
168. Wang H, Liu Y, Chen Y, Robinson H, Ke H (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949-30955 (Pubitemid 41291827)
169. Wang H, Liu Y, Hou J, Zheng M, Robinson H, Ke H (2007) Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci USA 3;104:5782-5787 (Pubitemid 47175611)
170. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281:21469-21479 (Pubitemid 44115485)
171. Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, Cai J, Ke H (2007) Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J 408:193-201 (Pubitemid 350206342)
172. Wang H, Yan Z, Yang S, Cai J, Robinson H, Ke H (2008) Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 47: 12760-12768
173. Wang H, Ye M, Robinson H, Francis SH, Ke H (2008) Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol 73:104-110 (Pubitemid 350294201)
174. Weeks JL 2nd, Zoraghi R, Francis SH, Corbin JD (2007) N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry 46:10353-10364 (Pubitemid 350067628)
175. Wernet W, Flockerzi V, Hofmann F (1989) The cDNA of the two isoforms of bovine cGMPdependent protein kinase. FEBS Lett 251:191-196 (Pubitemid 19181868)
176. Wilson LS, Elbatarny HS, Crawley SW, Bennett BM, Maurice DH (2008) Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMPmediated regulation of platelet functions. Proc Natl Acad Sci USA 105:13650-13655
177. Wu AY, Tang XB, Martinez SE, Ikeda K, Beavo JA (2004) Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 279: 37928-37938 (Pubitemid 39195508)
178. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 288:1822-1825 (Pubitemid 30399019)
179. Xu RX, Rocque WJ, Lambert MH, Vanderwall DE, Luther MA, Nolte RT (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol 337:355-365 (Pubitemid 38293404)
180. Yamamoto T, Yamamoto S, Osborne JC Jr, Manganiello VC, Vaughan M, Hidaka H (1983) Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase. J Biol Chem 258:14173-14177 (Pubitemid 14217936)
181. Yan C, Zhao AZ, Bentley JK, Beavo JA (1996) The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271:25699-25706 (Pubitemid 26337952)
182. Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274:14909-14917
183. Zaccolo M, Pozzan T (2002) Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295:1711-1715 (Pubitemid 34202906)
184. Zhang KYJ (2006) Crystal structure of phosphodiesterase families and the potential for rational drug design. In: Beavo J, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterase in health and disease. CRC Press, Boca Raton, pp 583-605
185. Zhang W, Ke H, Colman RW (2002) Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and sitedirected mutagenesis. Mol Pharmacol 62:514-520 (Pubitemid 36329369)
186. Zhang X, Feng Q, Cote RH (2005) Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis Sci 46:3060-3066 (Pubitemid 44264288)
187. Zhang XJ, Skiba NP, Cote RH (2009) Structural requirements of the photoreceptor phosphodiesterase {gamma}-subunit for inhibition of rod PDE6 holoenzyme and for its activation by transducin. J Biol Chem 285:4455-4463
188. Zhao Y, Zhang HT, ODonnell JM (2003) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther 305:565-572 (Pubitemid 36459171)
189. Zhu B, Strada SJ (2007) The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 7: 437-454 (Pubitemid 46358655)
190. Zoraghi R, Corbin JD, Francis SH (2004) Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. Mol Pharmacol 65:267-278 (Pubitemid 38134253)
191. Zoraghi R, Bessay EP, Corbin JD, Francis SH (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280:12051-12063 (Pubitemid 40418524)
192. Zoraghi R, Francis SH, Corbin JD (2007) Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cGMP and inhibitors. Biochemistry 46: 13554-13563 (Pubitemid 350209951)